Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542445 | 0.82 | TSHR (0.37) | PKMKDM4EGPR35MAPK1NPC1 | |
| SCHEMBL2235253 | 0.79 | LMNA (0.37) | PKMGPR35ALDH1A1TSHRMAPT | |
| SCHEMBL1492106 | 0.79 | CSF1R (0.42) | — | |
| SCHEMBL2235201 | 0.79 | ALDH1A1 (0.40) | PKMGPR35MAPK1ALDH1A1TSHR | |
| SCHEMBL9931007 | 0.79 | GABRP (0.37) | GPR35MAPK1ALDH1A1TSHRMAPT | |
| SCHEMBL9930841 | 0.79 | YTHDC1 (0.35) | PKMMAPK1ALDH1A1TSHRMAPT | |
| SCHEMBL18633737 | 0.79 | ALDH1A1 (0.33) | PKMKDM4EGPR35MAPK1NPC1 | |
| SCHEMBL422304 | 0.77 | NPC1 (0.53) | PKMKDM4EMAPK1NPC1ALDH1A1 | |
| SCHEMBL30845424 | 0.77 | ASPH (0.35) | PKMKDM4EMAPK1TSHRMAPT | |
| SCHEMBL9930522 | 0.76 | DAO (0.33) | KDM4EALDH1A1TSHRMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PKM 803/4885KDM4E 3645/4885GPR35 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.